PHARMACEUTICAL COMPOSITION CONTAINING TACROLIMUS (FK506)

• 1. 含有人甲状旁腺激素的药物成分及含有该成分的用于鼻内给药的药物组合物 [P] . 中国专利： CN100518819C . 2009.07.29
• 2. 含有人甲状旁腺激素的药物成分及含有该成分的用于鼻内给药的药物组合物 [P] . 中国专利： CN1440294A . 2003-09-03
• 3. PHARMACEUTICAL COMPOSITION CONTAINING TACROLIMUS (FK506) [P] . HU0000587A3 . 2001-12-28

  机译： 含有滑石粉的药物成分（FK506）

• 4. PHARMACEUTICAL COMPOSITION CONTAINING TACROLIMUS (FK506) [P] . HU0000587A2 . 2000-09-28

  机译： 含有滑石粉的药物成分（FK506）

• 5. FK506 PHARMACEUTICAL COMPOSITIONS CONTAINING FK506 DERIVATIVES AND THEIR USE FOR THE TREATMENT OF FUNGAL INFECTION BY CRYPTOCOCCUS SP. AND CANDIDA SP. FUNGI [P] . 韩国专利： KR101632042B1 . 2016-06-21

  机译： 包含FK506衍生物的FK506药物组合物及其在治疗隐球菌SP真菌感染中的用途。和CANDIDA SP。菌类

• 1. A retrospective analysis of the safety and efficacy of low dose tacrolimus (FK506) for living donor liver transplant recipients [J] . Zhengshan Wu, Qingyang Meng, Yongxiang Xia, 生物医学研究杂志（英文版） . 2013,第004期
• 2. A retrospective analysis of the safety and efficacy of low dose tacrolimus （FK506） for living donor liver transplant recipients [J] . Zhengshan Wu, Qingyang Meng, Yongxiang Xia, 生物医学研究杂志：英文版 . 2013,第004期
• 3. Effects of tacrolimus (FK506) on sciatic nerve regeneration in rats [J] . Weiguo Zhang, Decheng Lü, Shouyu Wang, 中国神经再生研究（英文版） . 2009,第005期
• 4. Neuroprotective effects of tacrolimus (FK506) in a model of ischemic cortical cell cultures: role of glutamate uptake and FK506 binding protein 12 kDa. [J] . Labrande C, Velly L, Canolle B, Neuroscience: An International Journal under the Editorial Direction of IBRO . 2006,第1期
• 5. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. [J] . Wiesner RH Transplantation: Official Journal of the Transplantation Society . 1998,第4期
• 6. FK506 (tacrolimus) and endothelin combined treatment induces mobility of melanoblasts: new insights into follicular vitiligo repigmentation induced by topical tacrolimus on sun-exposed skin. [J] . Lan CC, Wu CS, Chen GS, British Journal of Dermatology . 2011,第3期
• 7. Development of a Universal Method Based on Ionic Liquids for Determination of Enantiomeric Compositions of Pharmaceutical Products [C] . Chieu D. TVan Symposium on ionic liquid applications: pharmaceuticals, therapeutics, and biotechnology . 2010
• 8. Determination of enantiomeric composition of pharmaceutical compounds using electrospray ionization mass spectrometry (ESI-MS). [D] . Wang, Beibei. 2007
• 9. Tacrolimus (FK506) and the Pharmaceutical/Academic/Regulatory Gauntlet [O] . Thomas E. Starzl, Satoru Todo, Anthony J. Demetris, -1
• 10. Tacrolimus (FK506) and the pharmaceutical/academic/regulatory gauntlet [O] . Starzl TE, Todo S, Demetris AJ, 1998
• 11. Local Tacrolimus (FK506) Delivery for Prevention of Acute Rejection in the Nonhuman Primate Delayed Mixed Chimerism Vascularized Composite Allograft ToleranceInduction Protocol. [R] . Cetrulo, C. L. 2016

• 1. The Treatment of Tacrolimus (FK506) for Psoriasis:One Case Report and Literature Analysis [J] . Wei-gang Cao ,Bao-an Qiu . 国际感染杂志（电子版） . 2013,第004期
• 2. The Treatment of Tacrolimus (FK506) for Psoriasis:One Case Report and Literature Analysis [J] . 无 . 国际感染杂志（电子版） . 2013,第004期
• 3. 免疫药物FK506在房水血液中含量的LC-MS-MS测定 [C] . 汪国权 ,陈放 ,盛耀华 . 中国有机质谱学第十一届全国学术大会 . 2001
• 4. 以改性分子筛和含有药物成分的缔合物作为选择性电极载体的应用研究 [A] . 张双艳 . 2017